^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Biofidelity

i
Other names: Biofidelity | BIOFIDELITY
Related tests:
Evidence

News

5ms
Biofidelity announces presentation of new data on novel genomic technology at AMP 2022 (Biofidelity Press Release)
"Biofidelity, a revolutionary genomic technology company, announced that new data from its breakthrough ASPYRE technology will be presented in a scientific poster at the upcoming Association for Molecular Pathology 2022 Annual Meeting, Nov. 1-5, in Phoenix, Ariz...The ASPYRE technology is used to create targeted, multi-gene biomarker panels that are ultra-sensitive, highly specific, and capable of returning results in as little as two days. Using the technology, Biofidelity has developed ASPYRE-Lung, a cost effective, simple and rapid assay that enables detection of multiple genomic biomarkers for patients diagnosed with non-small cell lung cancer (NSCLC)."
Clinical data
|
ASPYRE-Lung
5ms
New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA (Biofidelity Press Release)
"Biofidelity, a revolutionary genomic technology company, has developed a low-cost, simple and rapid assay for single-molecule detection of multiple gene fusions from RNA. A new scientific paper describes the assay and how detecting these fusions faster and at a lower cost has the potential to revolutionize patient care and make precision medicine globally accessible to more people...Published online in BMC Medical Genomics, the paper expands on a previous scientific report introducing the technology and details the RNA capabilities of ASPYRE®, which can analyze DNA and RNA concurrently from a single patient sample."
Clinical data
|
ASPYRE-Lung
7ms
Biofidelity granted key patents in US, Europe, and China (Biofidelity Press Release)
"Biofidelity...announced today the issuance of several new patents in the US, Europe, and China. The patents further strengthen the Company’s intellectual property position and the protection of the technology underpinning its first commercial product, ASPYRE-Lung®....Newly issued European patent EP3842549 will provide protection for ASPYRE until 2040 in key European countries."
Patent
|
ASPYRE-Lung
1year
Biofidelity raises $23M in Series A+ financing led by Octopus Ventures to launch ASPYRE technology (Biofidelity Press Release)
"Biofidelity...has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company’s first commercial diagnostic assay based on its breakthrough molecular technology."
Financing
|
ASPYRE-Lung